A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
医学
前列腺癌
肿瘤科
内科学
癌症研究
癌症
作者
Ben Tran,Hosein Kouros-Mehr,Anthony C. Fermin,Lisa G. Horvath,Felicia Roncolato,Matthew B. Rettig,Tanya B. Dorff,Scott T. Tagawa,Sumit K. Subudhi,Emmanuel S. Antonarakis,Andrew J. Armstrong,Daniel P. Petrylak,Karim Fizazi,Mark Salvati,Howard I. Scher